Agreement | Jotup

iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka

Retrieved on:

Monday, February 26, 2024

SAN, DVM, Lupus, PD-1, Cell, Agreement, Immune system

BRYAN, Texas and SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announces today that it has entered into an asset purchase agreement (“Agreement”) with Otsuka Pharmaceutical Co., Ltd. (“Otsuka”), pursuant to which Otsuka acquired iBio’s assets related to its early-stage programmed cell death protein 1 (“PD-1” ) agonist program. The transaction closed on February 25, 2024.

Key Points:

BRYAN, Texas and SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announces today that it has entered into an asset purchase agreement (“Agreement”) with Otsuka Pharmaceutical Co., Ltd. (“Otsuka”), pursuant to which Otsuka acquired iBio’s assets related to its early-stage programmed cell death protein 1 (“PD-1” ) agonist program.
Under the terms of the Agreement, iBio will receive an upfront payment of $1.0 million in cash at closing.
However, unlike PD-1 antagonists used in immuno-oncology, PD-1 agonists, like the one iBio is selling to Otsuka, are difficult to find.
At the same time, it provides a path forward for the PD-1 agonist program via further development by Otsuka.”

Bit Origin Ltd Signs Strategic Alliance Agreement with Mner.Club for Crypto Miner Deployment and Hosting

Retrieved on:

Friday, February 23, 2024

Bitcoin, Decentralized finance, Project, Agreement, Treasury, Mining, RWA, Club, Cryptocurrency

NEW YORK, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Bit Origin Ltd (NASDAQ: BTOG) ("Bit Origin" or the "Company"), an emerging growth company engaged in the crypto mining business with diversified expansion strategies, today announces it has entered into a Strategic Alliance Agreement (“Agreement”) with Mner.Club for crypto miner deployment.

Key Points:

NEW YORK, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Bit Origin Ltd (NASDAQ: BTOG) ("Bit Origin" or the "Company"), an emerging growth company engaged in the crypto mining business with diversified expansion strategies, today announces it has entered into a Strategic Alliance Agreement (“Agreement”) with Mner.Club for crypto miner deployment.
According to the Agreement, Bit Origin and Mner.Club will collaborate in the areas of crypto mining machine deployment and hosting, and Bit Origin will provide crypto mining consulting and hosting service provider selection services to Mner.Club.
This initiative involves the deployment of crypto mining machines, enabling holders to earn periodic distributions in a variety of assets, including Bitcoin, through staking.
Lucas Wang, Chairman and Chief Executive Officer of Bit Origin commented, “We are very pleased to partner with Mner.Club.

SANUWAVE Health Reports Stockholder Approval of SEPA Merger at Special Meeting of Stockholders

Retrieved on:

Thursday, February 22, 2024

Plan, Special, FDA, Combination, EDEN, Business analyst, Security (finance), Link, The Company, Agreement

EDEN PRAIRIE, MN, Feb. 22, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – SANUWAVE Health, Inc. (the "Company" or "SANUWAVE”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, today announced the result of its special meeting (the “Special Meeting”) to approve its business combination with SEP Acquisition Corp. The results, as reported in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on February 21, 2024 (Link), were as follows:

Key Points:

At a special meeting of stockholders on February 21, 2024, SANUWAVE stockholders approved the business combination with SEP Acquisition Corp. by a vote of 798,379,869 “for” and 5,221,765 “against” with 71,525 abstaining
EDEN PRAIRIE, MN, Feb. 22, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – SANUWAVE Health, Inc. (the "Company" or "SANUWAVE”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, today announced the result of its special meeting (the “Special Meeting”) to approve its business combination with SEP Acquisition Corp.
Both proposals were approved, each receiving the affirmative requisite vote of the holders of shares of the Company’s common stock.
Although Proposal 2 was approved, the adjournment of the Special Meeting to solicit additional proxies was not necessary because there were sufficient votes at the time of the Special Meeting to adopt Proposal 1.
Each proposal is described in detail in the Company’s definitive proxy statement filed with the SEC on January 22, 2024.

Semilux International Ltd. Announces Closing of up to $50 Million Common Stock Purchase Transaction with White Lion Capital

Retrieved on:

Thursday, February 22, 2024

ADB, Investment, Good, Sale, Lidar, Agreement

Taipei, Taiwan, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Semilux International Ltd. ("Semilux" or the "Company") (NASDAQ: SELX), a provider of application-specific integrated circuit (“ASIC”), LiDAR and ADB components and solutions, today announced that it has entered into a common stock purchase agreement (the "Agreement") with White Lion Capital, LLC ("White Lion Capital"), a Nevada limited liability company.

Key Points:

Taipei, Taiwan, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Semilux International Ltd. ("Semilux" or the "Company") (NASDAQ: SELX), a provider of application-specific integrated circuit (“ASIC”), LiDAR and ADB components and solutions, today announced that it has entered into a common stock purchase agreement (the "Agreement") with White Lion Capital, LLC ("White Lion Capital"), a Nevada limited liability company.
The Agreement governs a committed equity facility that provides the Company with the right, without the obligation, to sell White Lion Capital up to $50 million of its common stock, subject to certain limitations and conditions.
The Company intends to use the net proceeds from the transaction for working capital to advance the Company’s ASIC, LiDAR, and ADB technologies to meet the industry's growing demand for safety standards.
Dr. Yung-Peng Chang, Chairman of the Board, Director and Co-Chief Executive Officer of Semilux, commented, "We are pleased to announce the closing of the Agreement with White Lion Capital.

Gracell Biotechnologies Acquisition Completed

Retrieved on:

Thursday, February 22, 2024

The acquisition was structured as a merger of Merger Sub with and into the Company with the Company surviving the merger as a wholly owned subsidiary of Parent (the “Merger”).

Key Points:

The acquisition was structured as a merger of Merger Sub with and into the Company with the Company surviving the merger as a wholly owned subsidiary of Parent (the “Merger”).
As a result of the Merger, the Company ceased to be a publicly traded company and became a wholly owned subsidiary of Parent.
Such letters of transmittal must be completed before such holders can receive the applicable merger consideration.
Certificated ADS holders should wait to receive the letters of transmittal before surrendering their ADSs.

Puyi Announces Signing of First Supplementary Agreement to the Strategic Framework Agreement with White Group and Changes to Its Board and Management

Retrieved on:

Tuesday, February 20, 2024

Agreement, Entrepreneurship, Artificial intelligence, AI, Intelligence, Investment, Growth, NTUC, City, Vice, NUS, Politics, Parliament, Housing, Management

GUANGZHOU, China, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Puyi Inc. (NASDAQ: PUYI) (“Puyi” or the “Company”), a leading third-party wealth management services provider in China, today announces the signing of first supplementary agreement (the “Agreement”) with Singapore White Group Pte.

Key Points:

GUANGZHOU, China, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Puyi Inc. (NASDAQ: PUYI) (“Puyi” or the “Company”), a leading third-party wealth management services provider in China, today announces the signing of first supplementary agreement (the “Agreement”) with Singapore White Group Pte.
Ltd. (“White Group”) to the framework strategic agreement previously disclosed on February 2, 2024.
White Group and its partnerships will invest up to US$500 million in Puyi through new share subscriptions.
In addition, the directors of the board of Puyi (the “Board”) welcomes Mr. Peh Chin Hua in joining the Board and being appointed as the Chairman of the Board with immediate effect.

Gracell Biotechnologies Announces Shareholders’ Approval of Merger Agreement

Retrieved on:

Tuesday, February 20, 2024

Transaction, SAN, Cayman Islands, Plan, Autoimmune disease, Registrar, Proxy, Cayman, Companies Act, EGM, Agreement, Cancer, Airline

Pursuant to the Merger Agreement, in accordance with the applicable provisions of the Companies Act (As Revised) of the Cayman Islands, Merger Sub will merge with and into the Company at the effective time of the Merger, with the Company continuing as the surviving company and becoming a wholly owned subsidiary of the Parent (the “Merger”).

Key Points:

Pursuant to the Merger Agreement, in accordance with the applicable provisions of the Companies Act (As Revised) of the Cayman Islands, Merger Sub will merge with and into the Company at the effective time of the Merger, with the Company continuing as the surviving company and becoming a wholly owned subsidiary of the Parent (the “Merger”).
Each shareholder has one vote for each Ordinary Share.
The Merger Agreement, the Plan of Merger and the Transactions, were approved by approximately 99.9% of the total votes cast at the EGM.
The Merger is expected to close on or around February 22, 2024, subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement.

Graphite Bio Declares Special Dividend In Connection with Proposed Merger with Lenz Therapeutics

Retrieved on:

Friday, March 8, 2024

Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials, Plan, Graphite, Agreement, Holding company

Graphite Bio, Inc. (Nasdaq: GRPH) (“Graphite” or the “Company”) today announced that its Board of Directors has declared a special dividend in connection with the previously announced merger (the “Merger”) with Lenz Therapeutics, Inc. (“LENZ”) pursuant to the Agreement and Plan of Merger, dated November 14, 2023 (the “Merger Agreement”).

Key Points:

Graphite Bio, Inc. (Nasdaq: GRPH) (“Graphite” or the “Company”) today announced that its Board of Directors has declared a special dividend in connection with the previously announced merger (the “Merger”) with Lenz Therapeutics, Inc. (“LENZ”) pursuant to the Agreement and Plan of Merger, dated November 14, 2023 (the “Merger Agreement”).
The special dividend, which the Company estimates will be $1.03 per share of Graphite’s common stock, will be payable in cash to the stockholders of record as of March 18, 2024.
The exact amount of the special dividend will be calculated after deducting certain cash amounts as set forth in the Merger Agreement.
The special dividend will not exceed an amount equal to $60 million, subject to the adjustments set forth in the Merger Agreement.

Citi Trends Announces Refresh of Board of Directors

Retrieved on:

Thursday, February 29, 2024

Online Retail, Fashion, Other Retail, Retail, Department Stores, African Americans, Citi Trends, CTRN, Annual general meeting, Committee on Finance, Audit committee, Compensated emancipation, Citigroup, Investment, Agreement

Incumbent directors Brian Carney, Laurens Goff and Christina Francis will retire from the Board immediately following the 2024 Annual Meeting.

Key Points:

Incumbent directors Brian Carney, Laurens Goff and Christina Francis will retire from the Board immediately following the 2024 Annual Meeting.
The Board will remain capped at nine directors for the duration of the Agreement.
On behalf of the entire Board, I want to express my sincere gratitude to Brian, Laurens and Christina for their distinguished service and long-standing commitment to Citi Trends.
We believe the expertise provided by our new designees will help drive operational improvements and enhance Citi Trends’ plans for maximizing stockholder value."

Alcoa Announces Agreement With Alumina Limited on Terms and Process to Acquire Alumina Limited in All-Stock Transaction

Retrieved on:

Sunday, February 25, 2024

Alcoa and Alumina Limited have entered into an exclusivity and transaction process deed (“Process Deed”), and the Alumina Limited Board of Directors has confirmed that, subject to entry into a scheme implementation agreement, it intends to recommend the transaction to Alumina Limited shareholders.

Key Points:

Alcoa and Alumina Limited have entered into an exclusivity and transaction process deed (“Process Deed”), and the Alumina Limited Board of Directors has confirmed that, subject to entry into a scheme implementation agreement, it intends to recommend the transaction to Alumina Limited shareholders.
Under the all-scrip, or all-stock, transaction, Alumina Limited shareholders would receive consideration of 0.02854 Alcoa shares for each Alumina Limited share (the “Agreed Ratio”).
Under the Process Deed, Alcoa and Alumina Limited intend to finalize and enter into a scheme implementation agreement for the all-scrip transaction (the “Agreement”).
Upon completion of the Agreement, Alumina Limited shareholders would own 31.25 percent, and Alcoa shareholders would own 68.75 percent of the combined company.1
Alcoa is the sole operator of Alcoa World Alumina and Chemicals (AWAC), a joint venture (“JV”) with Alumina Limited.